{"name":"ArmaGen, Inc","slug":"armagen-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AGT-181","genericName":"AGT-181","slug":"agt-181","indication":"Other","status":"phase_1"},{"name":"AGT-182","genericName":"AGT-182","slug":"agt-182","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AGT-181","genericName":"AGT-181","slug":"agt-181","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGT-182","genericName":"AGT-182","slug":"agt-182","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQUTlfRkFoWThxZVkyNWJlZFJhTXlIQjhHOXlzcXJOdjlEdzNSdnViWTd5MVlFMi1DV2VlMnRtQkx2LWFwRmEtd3FpNDh4dlpmUFNvM2tiOHRjalRESTFFbC1VTjhCZDFfTExDRkQ0SzBpMW9rb2tsQVdjeG1uTFlQS3l6dkFDQUlHZ1dFRWNNMGFocjAzanlsa2t0blI?oc=5","date":"2025-11-07","type":"trial","source":"Market Data Forecast","summary":"Europe Blood Brain Barrier Technologies Market, Size,Share,2033 - Market Data Forecast","headline":"Europe Blood Brain Barrier Technologies Market, Size,Share,2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQdnU2QnZ2V1pYZUFLZDdCbGFieVg0NzZHRlBncUIyT0VqOVA4RHhGUTdyd2t6cDV3QnF2MFpXSmctcDlqSVBXYTlUMWtLRFJ6MTFFck9GVU14dVZoenEtUjhoSC1HV3ZnZUszQk5tMVBNb01QOGRUMGk1RGcwVUNXUVRzSWVoVmN6WlA3Q3dqZw?oc=5","date":"2024-03-13","type":"pipeline","source":"openPR.com","summary":"Hunter Syndrome Treatment Market Size, Share, Growth, and Opportunities 2023- 2030 - openPR.com","headline":"Hunter Syndrome Treatment Market Size, Share, Growth, and Opportunities 2023- 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPUVE0SnJqZU50MXU5UjV5WTAwRlBUaFNqWnFXOFlFYXhGU1FZdE54cktSbjV1Vk5WWXc1UUVzRFozTGNjc1plQkk3ZHhZTWNKelBId3dFRlNoNkNndWlRblV5dFdWVTlJVVdqMXQ1bXZfTU8zN2M4ZHdBX0c1ZDZIWks4Rkx1SkZOcUxVa3dTaWltWF9TdDctY1VRLUdROG5qNFFndFIyZGllUDAxdVlyN2ZDNUxmdUs0OWU3dzBLOE01Z05r?oc=5","date":"2020-04-27","type":"pipeline","source":"PR Newswire","summary":"JCR Pharmaceuticals announces Completion of Acquisition of ArmaGen, Inc. - PR Newswire","headline":"JCR Pharmaceuticals announces Completion of Acquisition of ArmaGen, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOc01YQ21CXzAyUkRYTllCeXhJQVF0dFJkNmdBVEVPcC0wR2ZvX0hMWEQ5R2d2bXhoSjJHejBobm9SbG1rSDZON19ReFdvTXBmLXhzeW1yQ2V4dEpXQUpRZEVZTDJkdzJvbXFtZ1N5eDJic0tmY1Q0d2Q2NWtzV1Y2cHBqaXRzeWd5NGFUU2F3?oc=5","date":"2020-04-01","type":"pipeline","source":"Fortune Business Insights","summary":"Mucopolysaccharidosis Treatment Market Size, Share, 2034 - Fortune Business Insights","headline":"Mucopolysaccharidosis Treatment Market Size, Share, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNdjNWOGxIc2lvWjVydV9aOWZmbnZOV0VEZ1BvTVR4NE9Mb0hyZUw1bVJCdjF4OE16akJCbE85OGw2azZZYTJkMU93bXlZaHJTRU0tZTAyc21rWVpZUW9JUDA3Um1RcjFKOVM2Z2hyTTU2b01VU1AyVWFmaHBtbmR3QXJMNDNMSGZDV0tXT2xmekN3M2l2R290YlVqa3RyMkJKUXBHZFlZb19lcW5DV1BORDIxamx6aVNjS0NZcmxDaHE0alNqTkgyZ3JzYlFpb1lUVF9vVw?oc=5","date":"2018-02-08","type":"pipeline","source":"PR Newswire","summary":"ArmaGen's AGT-181 Demonstrates Neurocognitive Benefit in Children with Severe MPS I - PR Newswire","headline":"ArmaGen's AGT-181 Demonstrates Neurocognitive Benefit in Children with Severe MPS I","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}